March 25, 2026
An insurer does not owe coverage in an antitrust suit accusing a pharmaceutical company of suppressing generic versions of the Parkinson's treatment Apokyn, a Maryland federal judge ruled, finding the dispute does not involve "securities claims" covered under the insurer's policy.
May 10, 2024
A Delaware federal judge has issued a sealed order refusing to dismiss drugmakers Sage Chemical Inc. and TruPharma's antitrust suit accusing rival Supernus Pharmaceuticals and others of suppressing generic versions of the Parkinson's treatment Apokyn.
March 21, 2023
The Federal Trade Commission told a Delaware federal court that patients could be significantly harmed by the types of distribution restrictions and other activity that Sage Chemical Inc. accuses its rivals of using to block generic competition for Parkinson's drug Apokyn.
December 21, 2022
Delaware's chief federal judge has ordered drugmaker Sage Chemical to retain new counsel if it wants to continue pursuing its antitrust suit against rival Supernus and others over Parkinson's drug Apokyn, finding that Sage's representation disregarded a court rule requiring an association with "Delaware counsel."